Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Host Immune Response in Patients Treated with Pre-operative Brachytherapy versus Neoadjuvant Chemoradiotherapy for Rectal Cancer
EF 2023-24
Résumé
In Canada, colorectal cancer (CRC) is the second leading cancer related cause of death in men and the third among women. This study looks specifically at rectal cancers which make up ~35% of CRC and have lower survival rates compared to colon cancer.
Currently, the main treatment for rectal cancer is radiation therapy (RT) and surgery. While RT has demonstrated efficacy in killing cancer cells, it also damages healthy tissue, including lymph nodes. Lymph nodes are vital in mounting an immune response to cancer. Emerging data has demonstrated that the host immune response plays a critical role in reducing malignancy. Because of this emerging knowledge of the immune system's role in combatting malignancy, is it important to find a way to deliver RT with minimal damage to the host immune system.
High Dose Rate Endorectal Brachytherapy, a more focused RT, can target the tumor while sparing lymph nodes. In fact, it may even help the immune system fight the cancer better compared to standard radiation therapy.
To test this idea, this study will analyze variations in the immune cell infiltration in each form of RT. Using immunohistochemistry, immune cell types will be analyzed before and after RT. The hypothesis is patients treated with brachytherapy will have more tumor inhibiting immune cells and better survival. If correct, this suggests that patients' immune systems are better equipped to fight cancer when treated with brachytherapy and may result in better survival outcomes. Specifically, the study aims to evaluate immune activation, gain deeper insights into the immune response triggered by RT, and establish whether the immune infiltration correlates with enhanced treatment outcomes for patients with rectal cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506279
Name
Starr Emma V
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Host Immune Response in Patients Treated with Pre-operative Brachytherapy versus Neoadjuvant Chemoradiotherapy for Rectal Cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adenocarcinoma; Brachytherapy; Disease Free Survival; External Beam Radiation Therapy; Immune Contexture; Immune Response; Radiotherapy; Rectal Cancer; Tumor Microenvironment
Abstract
In Canada, colorectal cancer (CRC) is the second leading cancer related cause of death in men and the third among women. This study looks specifically at rectal cancers which make up ~35% of CRC and have lower survival rates compared to colon cancer.
Currently, the main treatment for rectal cancer is radiation therapy (RT) and surgery. While RT has demonstrated efficacy in killing cancer cells, it also damages healthy tissue, including lymph nodes. Lymph nodes are vital in mounting an immune response to cancer. Emerging data has demonstrated that the host immune response plays a critical role in reducing malignancy. Because of this emerging knowledge of the immune system's role in combatting malignancy, is it important to find a way to deliver RT with minimal damage to the host immune system.
High Dose Rate Endorectal Brachytherapy, a more focused RT, can target the tumor while sparing lymph nodes. In fact, it may even help the immune system fight the cancer better compared to standard radiation therapy.
To test this idea, this study will analyze variations in the immune cell infiltration in each form of RT. Using immunohistochemistry, immune cell types will be analyzed before and after RT. The hypothesis is patients treated with brachytherapy will have more tumor inhibiting immune cells and better survival. If correct, this suggests that patients' immune systems are better equipped to fight cancer when treated with brachytherapy and may result in better survival outcomes. Specifically, the study aims to evaluate immune activation, gain deeper insights into the immune response triggered by RT, and establish whether the immune infiltration correlates with enhanced treatment outcomes for patients with rectal cancer.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Starr, Emma V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~